Suppr超能文献

在中国,不相关的结节性硬化症患者的肾脏表型与基因型相关。

Renal phenotypes correlate with genotypes in unrelated individuals with tuberous sclerosis complex in China.

机构信息

Department of Urology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha City, 410008, Hunan Province, People's Republic of China.

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha City, 410008, Hunan Province, People's Republic of China.

出版信息

Orphanet J Rare Dis. 2022 Jul 23;17(1):288. doi: 10.1186/s13023-022-02443-1.

Abstract

PURPOSE

To explore the relationship between the genotype and renal phenotype in a Chinese cohort and guide clinical decision-making for treating tuberous sclerosis complex (TSC).

MATERIALS AND METHODS

We reviewed 173 patients with definite TSC at three centers in China from September 2014 to September 2020. All the patients underwent TSC1 and TSC2 genetic testing as well as renal phenotypic evaluation. All analyses were performed using the SPSS software, version 19.0, with a cut-off P value of 0.05 considered statistically significant.

RESULTS

We identified variants in 93% (161/173) cases, including 16% TSC1 and 77% TSC2 variants. Analysis of the relationship between the genotype and renal phenotype, revealed that those with TSC2 variants were more likely to develop severe renal AML (> 4) (P = 0.044). In terms of treatment, TSC2 variants were more likely to undergo nephrectomy/partial nephrectomy (P = 0.036) and receive mTOR medication such as everolimus (P < 0.001). However, there was no significant difference between the two groups in terms of their response to the everolimus treatment.

CONCLUSION

Patients with TSC2 variants exhibit more severe renal phenotypes, especially those associated with renal angiomyolipomas (AML), and they often require nephrectomy/partial nephrectomy or mTOR medication. Detection of the genotype is helpful in TSC management.

摘要

目的

探索中国队列中基因型与肾表型的关系,为治疗结节性硬化症(TSC)提供临床决策依据。

材料与方法

我们回顾了 2014 年 9 月至 2020 年 9 月期间在中国三家中心确诊为 TSC 的 173 例患者。所有患者均接受 TSC1 和 TSC2 基因检测和肾表型评估。所有分析均使用 SPSS 软件,版本 19.0 进行,P 值<0.05 为统计学显著。

结果

我们发现 93%(161/173)的病例存在变异,包括 16%的 TSC1 和 77%的 TSC2 变异。基因型与肾表型的关系分析显示,携带 TSC2 变异的患者更易发生严重的肾血管平滑肌脂肪瘤(AML,>4 级)(P=0.044)。在治疗方面,携带 TSC2 变异的患者更倾向于接受肾切除术/部分肾切除术(P=0.036)和 mTOR 药物治疗,如依维莫司(P<0.001)。然而,两组患者对依维莫司治疗的反应无显著差异。

结论

携带 TSC2 变异的 TSC 患者表现出更严重的肾表型,尤其是与肾血管平滑肌脂肪瘤(AML)相关的表型,他们通常需要肾切除术/部分肾切除术或 mTOR 药物治疗。基因型检测有助于 TSC 的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ed/9308181/aae41d741cc2/13023_2022_2443_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验